CASI News and Press, CASI Pharmaceuticals Inc. From 05/02/22

CASI PHARMACEUTICALS TO REPORT FIRST QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL MAY 12, 2022 PR Newswire ROCKVILLE, Md. and BEIJING , May 2, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused ...

Shares of CASI Pharmaceuticals Inc. (NASDAQ:CASI) traded today at $8.89, eclipsing its 52-week high. This new high was reached on above average trading volume as 62.7 million shares traded hands, while the average 30-day volume is approximately 431,000 shares. In the past 52 weeks, CASI ...

Casi Pharmaceuticals (CASI -9.4%), a biotech focused on U.S. and Chinese markets, is trading lower for the third straight session on Friday after announcing that it was added to a list of companies that have failed to comply with the U.S. listing rules. Since last month, the Securities and Ex...

CASI PHARMACEUTICALS STATEMENT ON STATUS UNDER HOLDING FOREIGN COMPANIES ACCOUNTABLE ACT PR Newswire ROCKVILLE, Md. and BEIJING , April 1, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on deve...

CASI Pharmaceuticals, Inc. (CASI) Q4 2021 Earnings Conference Call March 28, 2022 08:00 ET Company Participants Wei-Wu He - Chairman and Chief Executive Officer Wei Zhang - President Alex Zukiwski - Chief Medical Officer Jim Goldschmidt - Senior Vice President, Business Development Conference...

CASI Pharmaceuticals press release (NASDAQ:CASI): FY GAAP EPS of -$0.27 beats by $0.03. Revenue of $30.17M (+99.3% Y/Y) beats by $0.09M. For further details see: CASI Pharmaceuticals GAAP EPS of -$0.27 beats by $0.03, revenue of $30.17M beats by $0.09M

CASI PHARMACEUTICALS ANNOUNCES FULL-YEAR 2021 FINANCIAL RESULTS AND FOURTH QUARTER 2021 EVOMELA® REVENUE PR Newswire ~ EVOMELA ® (melphalan for injection) Fourth Quarter 2021 Revenue Continues Strong Upward Trend, exceeding guidance ~ ROCK...

ADN, BITF, CASI, ITRM, JEF, MNMD, SAIC, VERO, XPEV For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open

CASI PHARMACEUTICALS TO REPORT FOURTH QUARTER AND YEAR END 2021 FINANCIAL RESULTS AND HOST CONFERENCE CALL MARCH 28, 2022 PR Newswire ROCKVILLE, Md. and BEIJING , March 23, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. bi...

CASI Pharmaceuticals (NASDAQ:CASI) renewed an exclusive distribution agreement under which China Resources Pharmaceutical Commercial Group International Trading Co. will continue to be the sole distributor of Evomela (melphalan) for Injection in China. Evomela is used as a high-dose...